Synapse
⌘+K
Synapse
PulseExploreJournal ClubResearchersJournals
Instagram
HomeJournal ClubExplore
September 10, 2025Diabetology & Metabolic SyndromeOpen Access

Empagliflozin targeted the immune-related gene PIK3CA in type 2 diabetes mellitus treatment: network pharmacology analysis and experimental evidence

View Full Paper
Ask AI
Bookmark
Share

Authors

HZHeng ZhongGSGuoyang SunFDF. Du

Discussion

Loading...

Member takes

Overview

Observational analysis identifies empagliflozin's immune modulation through PIK3CA in T2DM, highlighting potential therapeutic pathways.

Key Points

  • Empagliflozin treatment reduced PIK3CA expression and cytokine levels in high glucose-induced macrophages.
  • 109 immune-related differentially expressed genes were identified in T2DM, with PIK3CA as a key regulator.
  • The study utilized molecular docking and single-cell RNA sequencing to explore the interaction of empagliflozin and PIK3CA.
  • Findings suggest empagliflozin's effects may stem from immune pathway modulation linked to PIK3CA.

Cite This Study

Zhong et al. (2025) studied this question.

synapsesocial.com/papers/68c1bb7854b1d3bfb60edddehttps://doi.org/10.1186/s13098-025-01895-2
View Full Paper
Ask AI
Bookmark
Share